Immunovant Inc. | Mid-cap | Healthcare
$16.42
-3.13%
| Immunovant Stock Comparison:
Immunovant vs VertexImmunovant vs RegeneronImmunovant vs Blueprint MedicinesImmunovant vs Roivant SciencesImmunovant vs Bio-TechneImmunovant vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2025

Income Metrics

Revenue 0
Operating Income -438.2M
Net Income -413.8M

Balance Sheet Metrics

Total Assets 776.2M
Total Liabilities 68.8M
Shareholders Equity 707.4M
Debt to Equity 0.10

Cash Flow Metrics

Operating Cash Flow -358.1M
Free Cash Flow -376.6M

Revenue & Profitability Trend

Immunovant Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue00000
Cost of Goods Sold-----
Gross Profit-----
Operating Expenses438.2M270.2M208.3M156.0M108.1M
Operating Income-438.2M-270.2M-208.3M-156.0M-108.1M
Pre-tax Income-412.9M-258.8M-211.0M-156.8M-107.8M
Income Tax891.0K567.0K9.0K-84.0K-358.0K
Net Income-413.8M-259.3M-211.0M-156.7M-107.4M
EPS (Diluted)--$1.88-$1.71-$1.43-$1.22

Income Statement Trend

Immunovant Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets767.7M665.8M404.3M512.9M409.0M
Non-Current Assets8.6M595.0K1.5M2.6M3.5M
Total Assets776.2M666.4M405.8M515.6M412.5M
Liabilities
Current Liabilities68.8M48.6M43.3M44.5M18.8M
Non-Current Liabilities0047.0K1.2M2.2M
Total Liabilities68.8M48.6M43.3M45.7M21.0M
Equity
Total Shareholders Equity707.4M617.8M362.5M469.8M391.5M

Balance Sheet Composition

Immunovant Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income-413.8M-259.3M-211.0M-156.7M-107.4M
Operating Cash Flow-358.1M-216.8M-183.4M-117.9M-88.5M
Investing Activities
Capital Expenditures-759.0K-360.0K-197.0K-254.0K-210.0K
Investing Cash Flow-759.0K-360.0K-197.0K-254.0K-210.0K
Financing Activities
Dividends Paid-----
Financing Cash Flow449.7M466.7M70.2M200.1M313.3M
Free Cash Flow-376.6M-214.6M-188.4M-106.4M-83.5M

Cash Flow Trend

Immunovant Key Financial Ratios

Valuation Ratios

Forward P/E -5.28
Price to Book 3.85
PEG Ratio -5.28

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -62.46%
Return on Assets -37.97%

Financial Health

Current Ratio 11.16
Debt to Equity 0.01
Beta 0.61

Per Share Data

EPS (TTM) -$2.73
Book Value per Share $4.16

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
imvt2.7B-3.85-62.46%0.00%0.01
Vertex 114.1B32.826.92-5.64%-8.91%10.00
Regeneron 55.3B13.021.8415.96%31.94%9.20
Blueprint Medicines 8.3B-120.0024.19-47.71%-27.70%208.50
Roivant Sciences 7.8B1.951.71-12.54%96.86%1.93
Bio-Techne 7.9B60.873.926.53%10.89%20.99

Financial data is updated regularly. All figures are in the company's reporting currency.